AMENDMENT NO. 2 TO STRATEGIC COLLABORATION AGREEMENTNektar Therapeutics • March 1st, 2022 • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment No. 2”) to the Agreement (as defined below) is entered into as of January 12, 2022 (the “Amendment No. 2 Effective Date”) by and between Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, Suite 100, San Francisco, California 94158 (“Nektar”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York, 10154 (“BMS”). Nektar and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.”
